NLS Pharmaceutics AG is developing therapies for patients with rare and complex central nervous system disorders (e.g., narcolepsy, idiopathic hypersomnia, and other rare sleep disorders), as well as neurodevelopmental disorders (e.g, attention deficit hyperactivity disorder). The company's lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy, and Nolazol for the treatment of ADHD. NLS Pharmaceutics was incorporated in 2015 and is based in Zurich, Switzerland.
What is Nls Pharmaceutics's quote symbol?
What is the 52 week high and low for Nls Pharmaceutics (NASDAQ: NLSP)?
How much is Nls Pharmaceutics stock worth today?
How much is Nls Pharmaceutics's stock price per share?
What is Nls Pharmaceutics's Market Cap?